Steatosis‑associated immune alterations and LIGHT‑signaling in hepatic neoplastic disease.
Clinical Science · 02.11.2026
DOI: 10.1042/cs20260772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, online erschienen am 02.11.2026. Verfasst von Maria Aguilar-Ballester und 10 weiteren Autor:innen. Beteiligte Einrichtung: INCLIVA Biomedical Research Institute, Valencia, Spain. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: MEC | Instituto de Salud Carlos III, Ministerio de Universidades, Proyecto Paula.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with higher incidence of hepatic neoplasia and may influence the tumor microenvironment through immune–metabolic mechanisms. In this study, the contribution of intrahepatic natural killer T (NKT) cells and the LIGHT/LTβR/HVEM axis to MASLD severity in patients with primary hepatic cancer (PHC) or colorectal cancer liver metastases (CRCLM) was investigated. Liver biopsies were analyzed and stratified by intrahepatic triglyceride (TG) content into Group I (LIGHT/LTBR/HVEM expression were assessed. Group II showed higher MASLD activity score (MAS), with the greatest score in CRCLM patients. Fibrosis percentage did not differ between groups, although MMP9 and SOX9 gene expression was elevated in Group II, consistent with enhanced extracellular matrix remodeling. The LIGHT/LTBR/HVEM axis gene expression did not differ between groups, but PHC patients from Group II displayed increased LIGHT/LTBR gene expression. Hepatic NKT2 cells were significantly elevated in Group II, more pronounced in CRCLM. In group II, NK-cell abundance inversely correlated with HVEM expression, an association that remained significant after FDR correction. In addition, TP53 mRNA levels were positively associated with expression of components of the LIGHT/LTBR/HVEM axis. Our data reveal associations between MASLD severity, intrahepatic immune-cell composition and the LIGHT/LTBR/HVEM pathway in patients with hepatic neoplastic disease, supporting further investigation of NKT cell subsets and LIGHT signaling as potential markers of the immune–metabolic alterations accompanying steatotic liver disease in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INCLIVA Biomedical Research Institute, Valencia, Spain.
- Universitat de Valencia, Valencia, Spain.
Förderung
- MEC | Instituto de Salud Carlos III
- Ministerio de Universidades
- Proyecto Paula
- GVA | Conselleria de Cultura, Educación y Ciencia, Generalitat Valenciana
Zitieren
APA
Aguilar-Ballester, M., Jiménez-Martí, E., Hurtado-Genovés, G., Martín-Vañó, S., Garcés-Albir, M., Sabater, L., Peiró, M., Bea-Serrano, C., Real, J. T., Martinez-Hervás, S., & González-Navarro, H. (2026). Steatosis‑associated immune alterations and LIGHT‑signaling in hepatic neoplastic disease. Clinical Science. https://doi.org/10.1042/cs20260772
Vancouver
Aguilar-Ballester M, Jiménez-Martí E, Hurtado-Genovés G, Martín-Vañó S, Garcés-Albir M, Sabater L, et al. Steatosis‑associated immune alterations and LIGHT‑signaling in hepatic neoplastic disease. Clinical Science. 2026. doi:10.1042/cs20260772
BibTeX
@article{AguilarBallester2026,
author = {Aguilar-Ballester, Maria and Jiménez-Martí, Elena and Hurtado-Genovés, Gema and Martín-Vañó, Susana and Garcés-Albir, Marina and Sabater, Luis and Peiró, Marta and Bea-Serrano, Carlos and Real, José T and Martinez-Hervás, Sergio and González-Navarro, Herminia},
title = {Steatosis‑associated immune alterations and LIGHT‑signaling in hepatic neoplastic disease},
journal = {Clinical Science},
year = {2026},
doi = {10.1042/cs20260772}
}
EUVIMED